Omalizumab ‘cuts seasonal asthma attacks in youth’March 17th, 2011 - 6:13 pm ICT by ANI
London, Mar 17 (ANI): A clinical trial has found that the drug omalizumab, sold under the brand name Xolair, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among inner-city children and youth.
The study enrolled 419 children and youths, aged 6 to 20 years, diagnosed with moderate to severe allergic asthma lasting more than one year.
The children came from Boston, Chicago, Cleveland, Dallas, Denver, New York City, Tucson, Ariz. and Washington, D.C.
In addition to standard therapy, half of the participants were assigned at random to receive omalizumab, and the other half a placebo.
Drug or placebo was delivered via an injection under the skin every two to four weeks over the 60-week period of study.
As the trial proceeded, participants returned to the clinic every three months for evaluation of their symptoms.
At the end of the study, the investigators found that, overall, children and adolescents who received omalizumab had a 25 percent reduction in days with symptoms and a 30 percent reduction in asthma attacks compared with those who received placebo.
Those who received omalizumab also had a 75 percent reduction in hospitalizations.
Importantly, the spring and fall increases in asthma attacks that were seen in the participants receiving placebo were almost eliminated in those participants receiving omalizumab.
“The spike in asthma attacks in the fall, which is associated with colds and other viral airway infections, disappeared in the kids in the omalizumab group,” said William Busse, the principal investigator of ICAC and professor of medicine at the University of Wisconsin-Madison.
“Because the drug specifically targets IgE, which is the antibody responsible for allergies, our observations show the possible interplay between allergies, respiratory viruses and IgE in provoking asthma attacks,” he said.
Children and adolescents who responded the best to omalizumab had positive skin tests for cockroach allergy and high levels of cockroach allergen in their homes.
The findings appeared in the New England Journal of Medicine. (ANI)
- Food allergies linked to higher risk of asthma attacks - Oct 04, 2010
- Kids with less Vitamin D more likely to have allergies - Feb 25, 2011
- Cell component that triggers cat allergy identified - Mar 10, 2011
- Children, males and blacks at high risk of food allergies - Oct 04, 2010
- Asthmic kids on steroids grow slightly shorter - Sep 04, 2012
- Low vitamin D levels associated with allergies in children - Feb 25, 2011
- Umbilical cord blood not the right indicator to measure allergy risk - Oct 06, 2010
- Sunshine likely to protect kids from eczema - Feb 05, 2012
- Allergy shots beneficial for some asthmatics, risky for others - Aug 09, 2010
- Screen tests to predict future asthma attacks not effective for certain patients - Sep 01, 2009
- Low vitamin D levels linked to lower lung function in asthmatic kids - Apr 16, 2010
- Pine bark extract naturally reduces hay fever symptoms - Jun 24, 2010
- Paracetamol doubles risk of asthma in kids - Nov 30, 2010
- Bedroom chemicals nearly double kids' allergy risk - Oct 21, 2010
- Asthmatic kids experience premature loss of lung function later in life - Jan 19, 2011
Tags: allergic asthma, antibody, asthma attacks, asthma symptoms, boston chicago, city tucson, denver new york, ige, inner city children, interplay, omalizumab, principal investigator, respiratory viruses, seasonal asthma, seasonal increases, spring and fall, tucson ariz, university of wisconsin madison, william busse, xolair